AI-Guided Identification of a Critical Enhancer Element Controlling Fetal Haemoglobin Genes HBG1 and HBG2: Implications for Sickle Cell Disease Therapy in Nigeria

Authors

  • Aimola Idowu Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Firdausi S. Muhammad Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author https://orcid.org/0009-0002-9293-0987
  • Aliyu Salihu Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Aliyu Muhammad Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author https://orcid.org/0000-0002-4167-7793
  • Idris Z. Sadiq Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Samuel A. Obo Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Precious N. Onuoha Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Favour O. Jaja Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Usman U. Umar Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Olamide E. Abolarin Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author
  • Ismail Adamu Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria Author

Keywords:

Fetal haemoglobin, HBG1, HBG2, Enformer, Sickle cell disease, Gene regulation

Abstract

Sickle cell disease (SCD) affects approximately 150,000 Nigerian children annually, with Nigeria bearing 75% of Africa's SCD burden. Reactivating fetal haemoglobin (HbF) genes HBG1 and HBG2 represents a promising therapeutic strategy. This study applied Enformer, a deep learning transformer model, to predict regulatory activity across a 393 kb region of chromosome 11 containing HBG1 and HBG2. The model predicted 5,313 genomic tracks including H3K27ac (active enhancer mark), DNase hypersensitivity, and CAGE (transcription) signals across 896 genomic bins. We identified a strong enhancer element at chr11:5,308,936-5,309,374 (438 bp) located 40 kb downstream of HBG1, with an H3K27ac signal of 0.661, the highest in the analysed region. This enhancer showed multiple characteristics of active regulatory DNA: high DNase accessibility (signal=15.0), CAGE peaks indicating nearby transcription, and JASPAR motif scanning (threshold ≥4.0) confirmed binding sites for GATA1 (6 matches, top score 7.59) and TAL1::TCF3 (2 matches, top score 9.17); no KLF1 motif was detected at this locus. Additionally, we confirmed the β-globin Locus Control Region (LCR) approximately 118 kb upstream (H3K27ac=0.201). Both HBG1 and HBG2 share these regulatory elements, enabling coordinated expression. This computational analysis provides precise molecular coordinates for a candidate HbF regulatory enhancer that may contribute to BCL11A-mediated repression, pending experimental validation, establishing a foundation for developing targeted gene therapies for SCD treatment in resource-limited settings.

Downloads

Download data is not yet available.

References

Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., and Steinberg, M. H. (2011). Fetal hemoglobin in sickle cell anemia. Blood, 118(1), 19–27. https://doi.org/10.1182/blood-2011-03-325258

Avsec, Ž., Agarwal, V., Visentin, D., Ledsam, J. R., Grabska-Barwinska, A., Taylor, K. R., Assael, Y., Jumper, J., Kohli, P., and Kelley, D. R. (2021). Effective gene expression prediction from sequence by integrating long-range interactions. Nature Methods, 18(10), 1196–1203. https://doi.org/10.1038/s41592-021-01252-x

Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., Boyer, L. A., Young, R. A., and Jaenisch, R. (2010). Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proceedings of the National Academy of Sciences, 107(50), 21931–21936. https://doi.org/10.1073/pnas.1016071107

FDA. (2023). FDA approves first gene therapies to treat patients with sickle cell disease. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

Castro-Mondragon, J. A., Riudavets-Puig, R., Rauluseviciute, I., Berhanu Lemma, R., Turchi, L., Blanc-Mathieu, R., Lucas, J., Boddie, P., Khan, A., Manosalva Perez, N., Fornes, O., Leung, T. Y., Aguirre, A., Hammal, F., Schmelter, D., Baranasic, D., Ballester, B., Sandelin, A., Lenhard, B., Vandepoele, K., Wasserman, W. W., Parcy, F., and Mathelier, A. (2022). JASPAR 2022: The 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Research, 50(D1), D165-D173. https://doi.org/10.1093/nar/gkab1113

Grevet, J. D., Lan, X., Hamagami, N., Edwards, C. R., Sankaranarayanan, L., Ji, X., Bhardwaj, S. K., Face, C. J., Posocco, D. F., Abdulmalik, O., Keller, C. A., Giardine, B., Sidoli, S., Garcia, B. A., Chou, S. T., Liebhaber, S. A., Hardison, R. C., and Blobel, G. A. (2021). 3'HS1 CTCF binding site in human beta-globin locus regulates fetal hemoglobin expression. eLife, 10, e70557. https://doi.org/10.7554/eLife.70557

Muhammad, F. (2026). HBG1/HBG2 Fetal Hemoglobin Regulatory Analysis Using Enformer (Version 1.0.0) [Software]. Zenodo. https://doi.org/10.5281/zenodo.18824086

Piel, F. B., Hay, S. I., Gupta, S., Weatherall, D. J., and Williams, T. N. (2013). Global burden of sickle cell anaemia in children under five, 2010–2050: Modelling based on demographics, excess mortality, and interventions. PLOS Medicine, 10(7), e1001484. https://doi.org/10.1371/journal.pmed.1001484

Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K., Hirschhorn, J. N., Cantor, A. B., and Orkin, S. H. (2008). Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science, 322(5909), 1839–1842. https://doi.org/10.1126/science.1165409

Schoenfelder, S., and Fraser, P. (2019). Long-range enhancer–promoter contacts in gene expression control. Nature Reviews Genetics, 20(8), 437–455. https://doi.org/10.1038/s41576-019-0128-0

Ware, R. E., de Montalembert, M., Tshilolo, L., and Abboud, M. R. (2017). Sickle cell disease. The Lancet, 390(10091), 311–323. https://doi.org/10.1016/S0140-6736(17)30193-9

Wilber, A., Nienhuis, A. W., and Persons, D. A. (2011). Transcriptional regulation of fetal to adult hemoglobin switching: New therapeutic opportunities. Blood, 117(15), 3945–3953. https://doi.org/10.1182/blood-2010-11-316893

Additional Files

Published

2026-09-11

Data Availability Statement

All analysis code and processed data supporting the findings of this study are publicly available on GitHub at https://github.com/firdausicopywriter-crypto/hbg-enformer-analysis and archived on Zenodo at https://doi.org/10.5281/zenodo.18824086. All analyses were performed using publicly accessible tools and the human reference genome hg38.

How to Cite

AI-Guided Identification of a Critical Enhancer Element Controlling Fetal Haemoglobin Genes HBG1 and HBG2: Implications for Sickle Cell Disease Therapy in Nigeria. (2026). Nigerian Journal of Biochemistry and Molecular Biology, 40(3), 363-368. https://www.nsbmb.org.ng/journals/index.php/njbmb/article/view/678

Similar Articles

21-30 of 67

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)